TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis

Qiliu Peng1, Xianjun Lao1, Zhiping Chen2, Hao Lai2, Yan Deng1, Jian Wang1, Cuiju Mo1, Jingzhe Sui1, Junrong Wu1, Limin Zhai1, Shi Yang1, Xue Qin1, Shan Li1*

1 Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China, 2 Department of Occupational Health and Environmental Health, School of Public Health at Guangxi Medical University, Nanning, Guangxi, China, 3 Department of Gastrointestinal Surgery, Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China

Abstract

Background: The association between TP53 R72P and/or MDM2 SNP309 polymorphisms and hepatocellular carcinoma (HCC) risk has been widely reported, but results were inconsistent. To clarify the effects of these polymorphisms on HCC risk, an updated meta-analysis of all available studies was conducted.

Methods: Eligible articles were identified by search of databases including PubMed, Cochrane Library, EMBASE and Chinese Biomedical Literature database (CBM) for the period up to July 2013. Data were extracted by two independent authors and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated. Metaregression and subgroup analyses were performed to identify the source of heterogeneity.

Results: Finally, a total of 10 studies including 2,243 cases and 3,615 controls were available for MDM2 SNP309 polymorphism and 14 studies containing 4,855 cases and 6,630 controls were included for TP53 R72P polymorphism. With respect to MDM2 SNP309 polymorphism, significantly increased HCC risk was found in the overall population. In subgroup analysis by ethnicity and hepatitis virus infection status, significantly increased HCC risk was found in Asians, Caucasians, Africans, and HCV positive patients. With respect to TP53 R72P polymorphism, no significant association with HCC risk was observed in the overall and subgroup analyses. In the MDM2 SNP309–TP53 R72P interaction analysis, we found that subjects with MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype were associated with significantly increased risk of developing HCC as compared with the reference MDM2 309TT and TP53 Arg/Arg genotype.

Conclusions: We concluded that MDM2 SNP309 polymorphism may play an important role in the carcinogenesis of HCC. In addition, our findings further suggest that the combination of MDM2 SNP 309 and TP53 Arg72Pro genotypes confers higher risk to develop HCC. Further large and well-designed studies are needed to confirm this association.

Introduction

Liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), was the sixth most common cancer worldwide and the third most common cause of cancer mortality in 2008 [1]. In high-risk China, liver cancer was the third most common cancer with 402,000 new cases and the second most common cause of death from cancer with 372,000 deaths in 2008 [2]. Besides, HCC is the fastest growing cause of cancer-related deaths in men of USA [3]. Thus, liver cancer is a serious fatal disease worldwide and has caused serious damage to human health. HCC accounts for about 90% of all primary liver cancers, and there are marked variations among geographic regions, racial, and ethnic groups, and between men and women [4]. Most HCC cases (about 80%) occur in either sub-Saharan Africa or Eastern Asia, and China alone accounts for more than 50% of the world’s cases [4]. As a complex and multi-factorial process, hepatocellular carcinogenesis is still not fully understood [4,5]. Previous epidemiological studies have identified that major risk factors for the development of HCC are chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), liver cirrhosis, habitual alcohol abuse, and exposure to aflatoxin B1 [4,5]. However, most individuals with these known environmental risk factors never develop HCC while many HCC cases develop among individuals without those
known risk factors, suggesting that genetic factors also play an important role in hepatocellular carcinogenesis [5].

TP53 is a tumour suppressor that plays an important role in cell cycle regulation and the maintenance of genome integrity [6,7,8]. TP53 mediates the cellular response to DNA damage via effects on gene transcription, DNA synthesis and repair, genomic plasticity and apoptosis. Functional polymorphisms of the TP53 gene which influence the above activities of TP53 protein might be associated with human susceptibility to cancer. A common single nucleotide polymorphism in codon 72 of TP53 (rs1042522) causes the Arg to Pro amino acid substitution, and the 72Arg allele shows more efficient in inducing apoptosis [9] and lower ability in inducing cell cycle arrest and DNA repair [10,11]. In addition, the human homolog of mouse double minute 2 (MDM2), acting as a major negative regulator of the TP53 tumor suppressor protein, directly binds to the latter to inhibit its activity as a transcription factor, and ubiquinates it enhancing its proteolytic breakdown [12]. One polymorphism in the promoter region of MDM2, a T to G change at nucleotide 309 in the first intron (rs2279744), was associated with the enhanced MDM2 expression, and then attenuated function of the TP53 protein. Taken together, the two polymorphisms TP53 R72P and MDM2 SNP309 can accelerate carcinogenesis directly by affecting TP53 function and indirectly by down-regulation of TP53 via overexpression of MDM2, respectively. Hence, it is biologically reasonable to hypothesize a potential relationship between the TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk.

Over the last two decades, a number of case–control studies have been conducted to investigate the associations between TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk, but the results remain controversial and inconclusive. With respect to MDM2 SNP309 polymorphism, a meta-analysis by Ma et al. [13] found that the MDM2 SNP309 polymorphism was associated with an increased HCC risk in Asians and Caucasians, however, they failed to include all eligible studies in the meta-analysis [14,15,16], which make their conclusions questionable. With respect to TP53 R72P polymorphism, two meta-analyses [17,18] investigating the same hypothesis, quite similar in methods and performed almost at the same time, yielded different conclusions. Furthermore, the two previous meta-analyses did not cover all eligible studies. The exact relationship between genetic polymorphisms of TP53 R72P and MDM2 SNP309 and HCC susceptibility has not been entirely established. To provide the most comprehensive assessment of the associations between the TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk, we performed an updated meta-analysis of all available studies. The meta-analysis presented in this study aims to assess whether TP53 R72P and MDM2 SNP309 polymorphisms TP53 R72P and MDM2 SNP309 can accelerate carcinogenesis directly by affecting TP53 function and indirectly

Selection Criteria

Studies included in the meta-analysis were required to meet the following criteria: (1) Case–control studies which evaluated the association between TP53 R72P and/or MDM2 SNP309 polymorphisms and HCC risk; (2) used an unrelated case–control design; (3) had an odds ratio (OR) with 95% confidence interval (CI); and (4) control population did not contain malignant tumor patients. Conference abstracts, case reports, editorials, review articles, and letters were excluded.

Data Extraction

Two investigators (Xue Qin and Qiliu Peng) independently extracted data from the eligible studies. Data extracted from eligible studies included the first author’s name, publication date, country of origin, ethnicity, genotyping method, matching criteria, source of control, HCC confirmation, QC when genotyping, total numbers of cases and controls and genotype frequencies of cases and controls. The hepatitis virus infection status was additionally recorded for the stratified analysis. Two investigators checked the data extraction results and reached consensus on all of the data extracted.

Quality Score Assessment

Methodological quality was independently assessed by two reviewers (Xue Qin and Qiliu Peng), according to a set of predefined criteria (Table 1) based on the scale of Thakkinstian et al. [20]. The revised criteria cover the credibility of controls, the representativeness of cases, assessment of HCC, genotyping examination, Hardy-Weinberg equilibrium (HWE) in the control population, and association assessment. A third reviewer (Shan Li) was invited to the discussion if disagreement still existed. Scores ranged from 0 (lowest) to 12 (highest). Articles with scores less than 8 were considered “low-quality” studies, whereas those with scores equal to or higher than 8 were considered “high-quality” studies.

Statistical Analysis

Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated for each polymorphism in different comparison models, including allelic contrast, additive genetic models, recessive genetic model, and dominant genetic model.

The Q test and $I^2$ statistics were used to assess the statistical heterogeneity among studies [21,22]. If the result of the Q test was $P_Q <0.1$ or $I^2 \geq 50\%$, indicating the presence of heterogeneity, a random-effects model (the DerSimonian and Laird method) was used to estimate the summary ORs [23]; otherwise, when the result of the Q test was $P_Q \geq 0.1$ and $I^2 <50\%$, indicating the absence of heterogeneity, the fixed-effects model (the Mantel–Haenszel method) was used [24]. To explore the sources of heterogeneity among studies, we performed logistic metaregression and subgroup analyses. The following study characteristics were included as covariates in the metaregression analysis: genotyping methods (PCR-RFLP versus not PCR-RFLP), ethnicity (Caucasian population versus Asian population), quality score (high quality studies versus low quality studies), source of controls (Hospital-based versus Population-based), QC when genotyping (Yes versus no), and HCC confirmation (pathologically or histologically confirmed versus other diagnosis criteria). Subgroup

Methods

Search Strategy

This study was performed according to the proposal of Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [19]. We conducted a comprehensive literature search in PubMed, Cochrane Library, Embase, and Chinese Biomedical Literature database (CBM) databases up to July 01, 2013 using the following search strategy: (“liver cancer”,” hepatocellular carcinoma” or “HCC”) and (“TP53”, “P53”, “codon 72”, “Murine double minute 2”, or “MDM2”). There was no restriction on time period, sample size, population, language, or type of report. All eligible studies were retrieved and their references were checked for other relevant studies. The literature retrieval was performed in duplication by two independent reviewers (Xue Qin and Qiliu Peng). When multiple publications reported on the same or overlapping data, we chose the most recent or largest population.
analyses were conducted by ethnicity and hepatitis virus infection status. Galbraith plots analysis was performed for further exploration of the heterogeneity.

Sensitivity analysis was performed by sequential omission of individual studies. For each polymorphism, publication bias was evaluated using Begg’s funnel plot and Egger’s regression asymmetry test [25]. The HWE of the control population in each eligible study was tested using a goodness-of-fit Chi-square test. All analyses were performed using Stata software, version 12.0 (Stata Corp., College Station, TX). All p values were two-sided. To ensure the reliability and the accuracy of the results, two authors entered the data into the statistical software programs independently with the same results.

**Results**

**Study Characteristics**

Based on our search criteria, 25 studies relevant to the role of TP53 R72P and/or MDM2 SNP309 on HCC susceptibility were identified. Six of these articles were excluded including 3 publications containing overlapping data [26–28], and 3 were meta-analyses [13,17,18]. Manual search of references cited in the published studies did not reveal any additional articles. As a result, a total of 19 relevant studies including 16 English articles [14,15,27,29–41] and 3 Chinese papers (one was a dissertation of postgraduate student) [16,42,43] met the inclusion criteria for the meta-analysis (Figure S1). The main characteristics of the studies were presented in Table 2. Among them, 5 studies evaluated the MDM2 SNP309 polymorphism, 9 studies evaluated the TP53 R72P polymorphism, and 5 studies evaluated TP53 R72P and MDM2 SNP309 simultaneously. Therefore, a total of 10 studies including 2,243 cases and 3,615 controls were available for the meta-analysis of MDM2 SNP309 polymorphism and 14 studies containing 4,855 cases and 6,630 controls were included for TP53 R72P polymorphism. The sample size in these studies varied considerably, ranging from 183 to 3,727 individuals. Of all the eligible studies, 2 were conducted in Caucasians, 7 were in Asians, and 1 was in Africans for MDM2 SNP309 polymorphism; 9 were conducted in Asians, 4 in Caucasians, and 1 was in Africans for TP53 R72P polymorphism. Three studies were population-based and 16 were hospital-based studies. Fourteen articles of all eligible studies used quality control when genotyping and 4 studies in the present meta-analysis did not provide definite criteria for the HCC diagnosis. Several genotyping methods were used, including PCR-RFLP, TaqMan assay, and MALDI-TOF. The genotype distributions of the controls in 2 studies were not consistent with HWE for MDM2 SNP309 polymorphism [30,35] and 2 were not consistent with HWE for TP53 R72P polymorphism [36,38].

**Meta-analysis Results**

Table 3 lists the main results of this meta-analysis.
| First author (Year) | Country | Ethnicity | Sample size (case/control) | Genotyping methods | Matching criteria | Source of control | HCC confirmation | QC when Genotyping | SNPs | HWE(P value) | Quality scores |
|---------------------|---------|-----------|-----------------------------|--------------------|------------------|------------------|----------------|--------------------|------|-------------|----------------|
| Akkiz 2004          | Turkey  | Caucasian | 110/110                     | PCR-RFLP           | Age, gender, smoking, drinking | PB | HC             | Yes               | MDM2 SNP309 | 0.239 | –            | 9              |
| Lee 2009            | China   | Asian     | 58/138                       | PCR-RFLP           | Ethnicity         | HB | NA             | Yes               | MDM2 SNP309 | **0.048** | –            | 5              |
| Dharel 2006         | Japan   | Asian     | 187/296                      | TaqMan assay       | Drinking          | HB | HC             | Yes               | MDM2 SNP309 | 0.724 | –            | 7              |
| Ezzikouri 2011      | Morocco | African   | 96/222                       | PCR-RFLP           | Age, gender       | HB | NA             | Yes               | MDM2 SNP309, p53 Arg72Pro | 0.508 | 0.685 | 4          |
| Tomoda 2012         | Japan   | Asian     | 258/199                      | MALDI-TOF          | Age, gender, drinking | HB | HC             | No               | MDM2 SNP309 | 0.640 | –            | 8              |
| Vuolo 2011          | Italy   | Caucasian | 61/122                       | PCR-RFLP           | Age, gender       | PB | PC             | No               | MDM2 SNP309, p53 Arg72Pro | 0.127 | 0.428 | 7          |
| Wang 2012           | China   | Asian     | 310/794                      | PCR-RFLP           | Age, gender       | HB | HC             | Yes               | MDM2 SNP309 | 0.111 | –            | 7              |
| Yoon 2008           | Korea   | Asian     | 287/296                      | PCR-RFLP           | Gender            | HB | HC             | No               | MDM2 SNP309, p53 Arg72Pro | **0.063** | 0.978 | 8          |
| Yang 2013           | China   | Asian     | 350/326                      | TaqMan assay       | Age               | HB | PC             | Yes               | MDM2 SNP309, p53 Arg72Pro | 0.738 | 0.636 | 8          |
| Jiang 2008          | China   | Asian     | 1375/2352                    | PCR-RFLP           | Age, gender       | HB | PC             | Yes               | MDM2 SNP309, p53 Arg72Pro | 0.134 | 0.145 | 8          |
| Sumbul 2012         | Turkey  | Caucasian | 119/119                      | PCR-RFLP           | Age, gender, smoking, drinking | HB | HC             | Yes               | p53 Arg72Pro | –         | **0.022** | 9          |
| Leveri 2004         | Italy   | Caucasian | 86/254                       | PCR-RFLP           | NA               | HB | HC             | No               | p53 Arg72Pro | –         | 0.301        | 6          |
| Yu 1999             | China   | Asian     | 80/328                       | PCR-RFLP           | Smoking, drinking | HB | PC             | Yes               | p53 Arg72Pro | –         | **0.019**      | 6          |
| Anzola 2003         | Spain   | Caucasian | 97/111                       | PCR-SSCP           | Region            | HB | NA             | No               | p53 Arg72Pro | –         | 0.375        | 5          |
| Zhang 2012          | China   | Asian     | 985/992                      | TaqMan assay       | Age, gender       | HB | HC             | Yes               | p53 Arg72Pro | –         | 0.898        | 8          |
| Peng 2004           | China   | Asian     | 192/192                      | PCR-RFLP           | Age, gender, ethnicity | HB | PC             | Yes               | p53 Arg72Pro | –         | 0.481        | 7          |
| Son 2013            | Korea   | Asian     | 157/201                      | PCR-RFLP           | Age, gender, drinking | HB | NA             | Yes               | p53 Arg72Pro | –         | 0.086        | 7          |
| Xu 2011             | China   | Asian     | 501/548                      | PCR-RFLP           | Age, gender, region | PB | PC             | Yes               | p53 Arg72Pro | –         | 0.359        | 11         |
| Zhu 2005            | China   | Asian     | 469/567                      | PCR-RFLP           | Smoking, drinking | HB | HC             | Yes               | p53 Arg72Pro | –         | 0.321        | 8.25        |

SNP, Single nucleotide polymorphism; HC, Histologically confirmed; PC, Pathologically confirmed; NA, Not available; QC, Quality control; PB, Population-based; HB, Hospital-based; HWE, Hardy-Weinberg equilibrium in control population; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF, Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; PCR-SSCP, Polymerase chain reaction-single strand conformation polymorphism.

doi:10.1371/journal.pone.0082773.t002
| Comparison     | Population | No. of studies | Test of association | Mode | Test of heterogeneity |
|---------------|------------|---------------|---------------------|------|-----------------------|
|               |            |               | OR                  | 95% CI | P Value | x² | P₀ | I² |
| MDM2 SNP309   |            |               |                     |       |           |    |    |    |
| G vs. T       | Overall    | 10            | 1.371               | 1.153–1.631 | 0.000 | R | 39.11 | 0.000 | 77.0 |
|               | Caucasian  | 2             | 1.987               | 1.488–2.653 | 0.000 | F | 0.01 | 0.907 | 0.0 |
|               | Asian      | 7             | 1.249               | 1.039–1.501 | 0.018 | R | 26.58 | 0.000 | 77.4 |
|               | African    | 1             | 1.569               | 1.090–2.258 | 0.015 | – | – | – | – |
|               | HBV positive | 4         | 1.207               | 0.933–1.563 | 0.153 | R | 16.88 | 0.001 | 82.2 |
|               | HCV positive | 3         | 1.481               | 1.245–1.761 | 0.000 | F | 2.67 | 0.263 | 25.1 |
|               | High quality studies | 5       | 1.467               | 1.284–1.674 | 0.000 | F | 3.47 | 0.483 | 0.0 |
| GG vs. TT     | Overall    | 10            | 1.831               | 1.300–2.579 | 0.001 | R | 34.56 | 0.000 | 74.0 |
|               | Caucasian  | 2             | 3.604               | 1.991–6.524 | 0.000 | F | 0.00 | 0.974 | 0.0 |
|               | Asian      | 7             | 1.539               | 1.070–2.212 | 0.020 | R | 23.98 | 0.001 | 75.0 |
|               | African    | 1             | 2.604               | 1.079–6.280 | 0.033 | – | – | – | – |
|               | HBV positive | 4         | 1.416               | 0.864–2.322 | 0.168 | R | 14.82 | 0.002 | 79.8 |
|               | HCV positive | 3         | 2.198               | 1.542–3.134 | 0.000 | F | 1.65 | 0.437 | 0.0 |
|               | High quality studies | 5       | 2.096               | 1.567–2.803 | 0.000 | F | 2.39 | 0.665 | 0.0 |
| TG vs. TT     | Overall    | 10            | 1.416               | 1.126–1.780 | 0.003 | R | 20.48 | 0.015 | 56.1 |
|               | Caucasian  | 2             | 2.433               | 1.509–3.922 | 0.000 | F | 0.26 | 0.613 | 0.0 |
|               | Asian      | 7             | 1.242               | 0.989–1.560 | 0.062 | R | 11.32 | 0.079 | 47.0 |
|               | African    | 1             | 1.590               | 0.958–2.641 | 0.073 | – | – | – | – |
|               | HBV positive | 4         | 1.145               | 0.938–1.398 | 0.184 | F | 5.60 | 0.133 | 46.4 |
|               | HCV positive | 3         | 1.759               | 1.280–2.418 | 0.001 | F | 1.90 | 0.387 | 0.0 |
|               | High quality studies | 5       | 1.571               | 1.225–2.014 | 0.000 | F | 2.97 | 0.562 | 0.0 |
| GG vs. TG+TT  | Overall    | 10            | 1.396               | 1.148–1.703 | 0.001 | R | 19.51 | 0.021 | 53.9 |
|               | Caucasian  | 2             | 2.112               | 1.271–3.507 | 0.004 | F | 0.10 | 0.755 | 0.0 |
|               | Asian      | 7             | 1.298               | 1.053–1.601 | 0.015 | R | 1.20 | 0.977 | 0.0 |
|               | African    | 1             | 2.081               | 0.897–4.827 | 0.088 | – | – | – | – |
|               | HBV positive | 4         | 1.244               | 0.932–1.661 | 0.139 | R | 9.51 | 0.023 | 68.5 |
|               | HCV positive | 3         | 1.507               | 1.147–1.980 | 0.003 | F | 0.94 | 0.626 | 0.0 |
|               | High quality studies | 5       | 1.564               | 1.281–1.908 | 0.000 | F | 1.70 | 0.791 | 0.0 |
| GG+TG vs. TT  | Overall    | 10            | 1.577               | 1.209–2.058 | 0.001 | R | 31.08 | 0.000 | 71.0 |
|               | Caucasian  | 2             | 2.734               | 1.743–4.289 | 0.000 | F | 0.14 | 0.704 | 0.0 |
|               | Asian      | 7             | 1.377               | 1.036–1.830 | 0.028 | R | 19.71 | 0.003 | 69.6 |
|               | African    | 1             | 1.719               | 1.058–2.794 | 0.029 | – | – | – | – |
|               | HBV positive | 4         | 1.289               | 0.883–1.881 | 0.188 | R | 11.31 | 0.010 | 73.5 |
|               | HCV positive | 3         | 1.926               | 1.426–2.601 | 0.000 | F | 2.09 | 0.352 | 4.2 |
|               | High quality studies | 5       | 1.765               | 1.394–2.235 | 0.000 | F | 2.70 | 0.610 | 0.0 |
| p53 Arg72Pro  | Pro vs. Arg | Overall    | 14            | 1.045               | 0.938–1.164 | 0.424 | R | 38.51 | 0.000 | 66.2 |
|               | Caucasian  | 4             | 1.105               | 0.897–1.362 | 0.347 | F | 4.43 | 0.218 | 32.3 |
|               | Asian      | 9             | 1.017               | 0.899–1.151 | 0.788 | R | 30.97 | 0.000 | 74.2 |
|               | African    | 1             | 1.330               | 0.911–1.941 | 0.140 | – | – | – | – |
|               | HBV positive | 7         | 1.041               | 0.856–1.267 | 0.686 | R | 27.03 | 0.000 | 77.8 |
|               | HCV positive | 3         | 0.957               | 0.721–1.270 | 0.759 | F | 0.32 | 0.851 | 0.0 |
|               | High quality studies | 7       | 1.106               | 0.964–1.270 | 0.151 | R | 26.86 | 0.000 | 77.7 |
| ProPro vs. ArgArg | Overall | 14          | 1.132               | 0.887–1.446 | 0.319 | R | 43.70 | 0.000 | 70.2 |
|               | Caucasian  | 4             | 1.454               | 0.864–2.446 | 0.159 | F | 4.85 | 0.183 | 38.2 |
|               | Asian      | 9             | 1.044               | 0.805–1.356 | 0.744 | R | 33.12 | 0.000 | 75.8 |
|               | African    | 1             | 2.304               | 0.954–5.234 | 0.046 | – | – | – | – |
For the MDM2 SNP309 polymorphism, the between-study heterogeneity was significant when all 10 studies were pooled into meta-analysis ($I^2 > 50\%$, or $P_Q < 0.10$), thus, the random-effects model was used to pool the results. The results of pooling all studies showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in all genetic models (G vs. T: OR = 1.371, 95%CI: 1.153–1.631, $P = 0.000$; GG vs. TT: OR = 1.831, 95%CI: 1.300–2.579, $P = 0.001$; TG vs. TT: OR = 1.416, 95%CI: 1.126–1.780, $P = 0.003$; GG vs. TG + TT: OR = 1.398, 95%CI: 1.148–1.703, $P = 0.001$; GG+TG vs. TT: OR = 1.577, 95%CI: 1.209–2.058, $P = 0.001$).

In subgroup analyses by ethnicity, the results showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in Asians (G vs. T: OR = 1.249, 95%CI: 1.039–1.501, $P = 0.018$; GG vs. TT: OR = 1.539, 95%CI: 1.070–2.212, $P = 0.020$; GG vs. TG+TT: OR = 1.298, 95%CI: 1.053–1.601, $P = 0.015$; GG+TG vs. TT: OR = 1.377, 95%CI: 1.036–1.830, $P = 0.028$); Caucasians (G vs. T: OR = 1.987, 95%CI: 1.488–2.653, $P = 0.000$; GG vs. TT: OR = 3.604, 95%CI: 1.991–6.324, $P = 0.000$; TG + TT: OR = 2.433, 95%CI: 1.509–3.922, $P = 0.000$; GG vs. TG+TT: OR = 2.112, 95%CI: 1.271–3.507, $P = 0.004$; GG+TG vs. TT: OR = 2.734, 95%CI: 1.743–4.289, $P = 0.000$), and Africans (G vs. T: OR = 1.569, 95%CI: 1.090–2.258, $P = 0.015$; GG vs. TT: OR = 2.604, 95%CI: 1.079–6.280, $P = 0.033$; GG+TG vs. TT: OR = 1.719, 95%CI: 1.058–2.794, $P = 0.029$).

In subgroup analysis by hepatitis virus infection status, the results showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in HCV positive patients (G vs. T: OR = 1.481, 95%CI: 1.245–1.761, $P = 0.000$; GG vs. TT: OR = 2.198, 95%CI: 1.542–3.134, $P = 0.000$; TG vs. TT: OR = 1.759, 95%CI: 1.280–2.418, $P = 0.001$; GG vs. TG + TT: OR = 1.507, 95%CI: 1.147–1.980, $P = 0.003$; GG+TG vs. TT: OR = 1.926, 95%CI: 1.426–2.601, $P = 0.000$) but not in HBV positive subjects.

For the TP53 R72P polymorphism, the between-study heterogeneity was also significant when all 14 eligible studies were pooled into meta-analysis ($I^2 > 50\%$, or $P_Q < 0.10$), thus the random-effects model was used to pool the results. The meta-analysis results showed that the TP53 R72P polymorphism was not associated with increased HCC risk in the overall populations. In the stratified analyses by ethnicity and hepatitis virus infection status, statistically significant associations were also not observed in all subgroups (Figure 2).

For the MDM2 SNP309–TP53 R72P interaction analysis, the between-study heterogeneity was not significant in most of subgroups when all three eligible studies were pooled into meta-analysis ($I^2 \leq 50\%$, and $P_Q > 0.10$; Table 4), thus the fix-effects model was used to pool the results. In comparison to the reference MDM2 309TT and p53 Arg/Arg genotype, subjects with the MDM2 309TT and TP53 Pro/Pro genotype (OR = 1.996, 95%CI: 1.481–2.653, $P = 0.000$) had a significantly increased HCC risk ($P = 0.000$).
For the MDM2 SNP309 polymorphism, the $I^2$ values of heterogeneity were greater than 50% and the $P$ values were lower than 0.10 in all genetic comparison models (additive model GG vs. TT and TG vs. TT, recessive model GG vs. TG+TT, and dominant model GG+TG vs. TT) in the overall populations, which indicated statistically significant heterogeneity among studies. To explore the sources of heterogeneity, we performed metaregression and subgroup analyses. Metaregression analysis of data showed that the ethnicity and Quality scores were the major sources which contributed to heterogeneity (regression coefficient = 0.114, 95%CI: 0.075–0.153, p = 0.003 for ethnicity and regression coefficient = 0.217, 95%CI: 0.093–0.341, p = 0.016 for Quality scores, respectively). The Genotyping methods, HCC sources which contributed to heterogeneity (regression coefficient = 0.217, 95%CI: 0.093–0.341, p = 0.016 for Quality scores, respectively). The Genotyping methods, HCC sources which contributed to heterogeneity (regression coefficient = 0.217, 95%CI: 0.093–0.341, p = 0.016 for Quality scores, respectively). The Genotyping methods, HCC sources which contributed to heterogeneity (regression coefficient = 0.217, 95%CI: 0.093–0.341, p = 0.016 for Quality scores, respectively).

Heterogeneity Analysis

For the MDM2 SNP309 polymorphism, the $I^2$ values of heterogeneity were greater than 50% and the $P$ values were lower than 0.10 in all genetic comparison models (additive model GG vs. TT and TG vs. TT, recessive model GG vs. TG+TT, and dominant model GG+TG vs. TT) in the overall populations, which indicated statistically significant heterogeneity among studies. To explore the sources of heterogeneity, we performed metaregression and subgroup analyses. Metaregression analysis of data showed that the ethnicity and Quality scores were the major sources which contributed to heterogeneity (regression coefficient = 0.114, 95%CI: 0.075–0.153, p = 0.003 for ethnicity and regression coefficient = 0.217, 95%CI: 0.093–0.341, p = 0.016 for Quality scores, respectively). The Genotyping methods, HCC confirmation, Source of control, and QC when genotyping were not effect modifiers. Subsequently, we performed subgroup analyses by ethnicity and hepatitis virus infection status. However, heterogeneity still existed in all the above genetic comparison models in Asians and HBV positive subgroup (Table 3). To further investigate the heterogeneity, we performed Galbraith plots analysis to identify the outliers which might contribute to the heterogeneity. Our results showed that the studies Jiang et al. [16] and Yang et al. [15] were outliers in all the above four genetic comparison models in the overall populations (Figure 3). All $I^2$ values decreased obviously and $P$ values were greater than 0.10 after excluding the two studies Jiang et al. [16] and Yang et al. [15] in all genetic comparison models in the overall populations, Asians and HBV positive subgroup. However, the significance of the summary ORs for the MDM2 SNP309 polymorphism in different comparison models in the overall populations, Asians and HBV positive subgroup were not influenced by omitting the two studies (Data not shown).

For the TP53 R72P polymorphism, significant between-study heterogeneity was also observed in the pooling analyses of total available studies (the $I^2$ values of heterogeneity were greater than 50% and the $P$ values were lower than 0.10 for additive model ProPro vs. ArgArg, recessive model ProPro vs. ArgPro+ArgArg, and dominant model ProPro+ArgPro vs. ArgArg). Metaregression analysis showed that the Quality scores was the major source heterogeneity (regression coefficient = 0.127, 95%CI: 0.051–0.203, p = 0.001). The Ethnicity, Genotyping methods, HCC confirmation, Source of control, and QC when genotyping were not effect modifiers. Galbraith plots analysis indicated that the studies by Jiang et al. [16] and Yoon et al. [35] were spotted as the major source of the heterogeneity (Figure 4). The $I^2$ values decreased obviously and $P$ values were greater than 0.10 after excluding the two studies Jiang et al. [16] and Yoon et al. [35] in the overall populations, Asians and HBV positive subgroup. However, the significance of the ORs for the TP53 R72P polymorphism in the overall populations, Asians and HBV positive subgroup were not changed by excluding the two studies.

Sensitivity Analysis

Sensitivity analysis was performed by sequential omission of individual studies for both MDM2 SNP309 and TP53 R72P polymorphisms. For analyses of pooling more than three individual studies, the significance of ORs was not influenced excessively by omitting any single study (data not shown). For the MDM2 SNP309 polymorphism, sensitivity analysis was further performed by omitting the studies by Leu et al. [30] and Yoon et al. [35] in which the control populations were not in accordance with HWE. The significance of all ORs was not altered after excluding these two studies. For the TP53 R72P polymorphism, a sensitivity analysis was also further performed by omitting those two studies by Sumbul et al. [36] and Yu et al. [38] in which the control populations were deviated from HWE, and the significance of all ORs was also not altered.

Publication Bias

Begg’s funnel plot and Egger’s test were performed to access the publication bias in this meta-analysis. Funnel plot shapes did not reveal obvious evidence of asymmetry, and all the p values of Egger’s tests were more than 0.05 for both MDM2 SNP309 and TP53 R72P polymorphisms, providing statistical evidence of the funnel plots’ symmetry (Figure S2). The results suggested that publication bias was not evident in this meta-analysis.

Discussion

Previous studies investigating the associations between MDM2 SNP309 and/or TP53 R72P polymorphisms and HCC risk have provided inconsistent results, and most of those studies involved no more than a few hundred HCC cases, which is too few to assess any genetic effects reliably. Meta-analysis has been recognized as an important tool to more precisely define the effect of selected genetic polymorphisms on the risk for disease and to identify potentially important sources of between-study heterogeneity. Hence, we performed this meta-analysis including all available studies to provide the most comprehensive assessment of the associations between the MDM2 SNP309 and TP53 R72P polymorphisms and HCC risk. Our results suggested that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in the overall populations, different ethnic subgroups, and HCV positive patients. However, our data did not support a genetic association between the TP53 R72P polymorphism and HCC risk. In the MDM2 SNP309–TP53 R72P interaction analysis, we found that individuals with MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309TG and TP53 Pro/Pro genotype, and MDM2 309GG and TP53 Pro/Pro genotype had significantly increased HCC risk compared to those with the reference MDM2 309TT and TP53 Arg/Arg genotype.

As a tumor suppressor, TP53 could lead to cell growth arrest and/or apoptosis in response to DNA damage and other cellular stresses [44]. The TP53 function is controlled by MDM2, which binds to TP53 and prevents TP53-dependent cell cycle arrest or apoptosis [45]. On the other hand, the MDM2 promoter is regulated by TP53 [46]. The functional TP53 Arg72Pro polymorphism has been shown to depress the activities of TP53 in inducing apoptosis, cell cycle arrest, and DNA repair [10,11]. However, in the present meta-analysis, we found that TP53 R72P polymorphism was not significantly associated with the risk of HCC either in the overall combined analysis nor the stratified analyses according to ethnicity and hepatitis virus infection status, which was inconsistent with the previous meta-analysis conducted by Lv et al. [17] and Ding et al. [18]. The main factor that would contribute to the discrepancy is that the previous meta-analyses with relatively small sample size may have insufficient statistical power to detect a real association with HCC risk or may have generated a fluctuated risk estimate. This observation is not a surprise because the TP53 72Pro allele could induce cell cycle...
arrest and DNA repair more efficiently to prevent transformation of normal cells [10].

MDM2 is one of the central nodes in the TP53 pathway. The proper regulation of MDM2 levels has been shown to be vital for TP53 tumor suppression, and even a modest change in levels could affect the TP53 pathway and, subsequently, cancer development in mouse models [47]. The study by Bond et al. [48] revealed that SNP309 GG cell lines expressed higher levels of MDM2 (on average 8-fold mRNA and 4-fold protein levels) than TT cell lines, whereas intermediate protein levels (on average 1.9-fold) were observed in heterozygous (TG) cell lines. Furthermore, Hong et al. [49] showed that SNP309 GG carriers had significantly higher MDM2 mRNA expression in esophageal tissue than TT carriers, but the TG heterozygote did not confer an increased MDM2 transcription. Thus, there is obvious biological evidence for the effects of MDM2 SNP309 polymorphism on HCC risk. In the present meta-analysis, we found that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in the overall populations, different ethnic subgroups, and HCV positive patients. This functional relevance of MDM2 SNP309 polymorphism played an important role in the HCC development.

HBV belongs to a family of DNA viruses called hepadnaviruses. The oncogenic potential of HBV has been attributed to its ability to integrate into host cellular DNA, which, may activate neighboring cellular genes directly to offer a selective growth advantage to the liver cells. In addition, production of hepatitis B x (HBx) protein can act as a transactivator on various cellular genes for cell growth and tumorigenesis [50]. In contrast, HCV is a positive-stranded RNA virus the genome of which does not seem to integrate into hepatocyte’s genome [51]. Therefore, differences in carcinogenic mechanisms between these viruses may affect HCC development. In the present meta-analysis, we found that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in HCV positive patients but not in HBV positive subgroup, which is consistent with the study conducted by Dharel et al. [31]. The explanation for preferentially increased HCC risk of MDM2 SNP309 polymorphism in HCV positive patients but not in HBV positive subgroup is that the TP53 function in the HCV patients could have been indirectly suppressed by the heightened MDM2 levels, making them more vulnerable to cancer development.

Previous research has demonstrated an interaction between MDM2 and TP53 at the molecular level [52], and the combined effects of MDM2 SNP 309 and TP53 Arg?Pro have been examined in lung cancer, Li-Fraumeni syndrome and non-polypsis colorectal cancer, with conflicting results [53,54,55]. In the present meta-analysis, we included all available three studies to explore the interaction effects between TP53 Arg?Pro and MDM2 SNP309 polymorphisms on HCC risk. We found that subjects with the MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype present significantly increased risk of developing HCC as compared with the reference MDM2 309TT and TP53 Arg/Arg genotype. However, no any dose-effect relationship was found in the interaction analysis. To the best of our knowledge, this is the first meta-analysis to explore the
combined effects of MDM2 SNP 309 and TP53 Arg72Pro polymorphisms on HCC risk. These results suggested a possible interaction effect between the MDM2 309GG and the TP53 72 Pro/Pro genotype in increasing the risk of HCC carcinogenesis.

Heterogeneity is a potential problem when interpreting the results of a meta-analysis, and finding the sources of heterogeneity is one of the most important goals of meta-analysis [56]. In the present meta-analysis, significant between-study heterogeneity in the pooled analyses of total eligible studies was observed ($P_Q$ values for MDM2 SNP 309 and TP53 Arg72Pro polymorphisms were all

**Figure 2.** Subgroup analysis by ethnicity in the meta-analysis on the association between TP53 Arg72Pro polymorphism and HCC risk using a random-effect model (additive model ProPro vs. ArgArg).

doi:10.1371/journal.pone.0082773.g002

**Table 4.** Summary odds ratios with confidence intervals for joint effect of MDM2 SNP309 and TP53 R72P polymorphisms on HCC risk.

| TP53 Arg72Pro | MDM2 SNP309 | No. of studies | Test of association | Mode | Test of heterogeneity |
|---------------|-------------|----------------|---------------------|------|----------------------|
|               | OR          | 95% CI         | $P$ Value           |      |                     |
| Arg/Arg       | TT          | 3              | Reference           | F    | 1.92                 |
|               | TG          | 3              | 1.996               | 0.028|                     |
|               | GG          | 3              | 1.674               | 0.194|                     |
| Arg/Pro       | TT          | 3              | 1.066               | 0.771|                     |
|               | TG          | 3              | 1.627               | 0.013|                     |
|               | GG          | 3              | 1.315               | 0.247|                     |
| Pro/Pro       | TT          | 3              | 1.996               | 0.028|                     |
|               | TG          | 3              | 1.462               | 0.141|                     |
|               | GG          | 3              | 5.237               | 0.000|                     |

$P_Q$, $P$ value of Q-test for heterogeneity test; R, random-effects model, F, fixed-effects model.

doi:10.1371/journal.pone.0082773.t004
less than 0.10, and $I^2$ values were larger than 50.0%). To find the sources of heterogeneity, we performed subgroup analyses and. Subgroup analyses showed that the heterogeneity was still significant in Asians and HBV positive patients, while it was removed in the other subgroups, indicating that heterogeneity might result from the inconsistency of effects across those included studies from Asian population and HBV positive patients.

Metaregression analysis showed that the ethnicity and Quality scores were the major sources of heterogeneity for MDM2 SNP 309 polymorphism and the Quality scores was the major source heterogeneity for TP53 Arg72Pro polymorphism. Subsequently, we performed Galbraith plots to further investigate the heterogeneity. For the MDM2 SNP 309 polymorphism, Galbraith plots spotted 2 studies [15,16] as the outliers and the possible major

---

**Figure 3. Galbraith plots of MDM2 SNP309 polymorphism and HCC risk (additive model GG vs. TT).** The studies of Jiang et al. and Yang et al. were spotted as outliers.

doi:10.1371/journal.pone.0082773.g003

**Figure 4. Galbraith plots of TP53 Arg72Pro polymorphism and HCC risk (additive model ProPro vs. ArgArg).** The studies of Jiang et al. and Yoon et al. were spotted as outliers.

doi:10.1371/journal.pone.0082773.g004
sources of heterogeneity. For the TP53 Arg72Pro polymorphism, Galbraith plots also plotted 2 studies [16,35] as the outliers and the possible major source of heterogeneity. Interestingly, the studies spotted as the outliers were all from Asian populations and HBV positive subgroup, which further confirmed that the inconsistency of effects across those studies from the above population might be the major sources of heterogeneity in this meta-analysis. When excluding the studies of Yang et al. [15] and Jiang et al. [16] for MDM2 SNP 309 polymorphism and the studies of Jiang et al. [16] and Yoon et al. [35] for p53 Arg72Pro polymorphism, all $I^2$ values decreased lower than 50% and $P_Q$ values were larger than 0.10 in all genetic comparison models in the overall populations, Asians, and HBV positive subgroup. However, the summary ORs for the MDM2 SNP309 and TP53 Arg72Pro polymorphisms in different comparison models in the overall population and subgroup analyses were not material change by omitting the studies spotted as outliers, indicating that our results were robust and reliable.

Some possible limitations in this meta-analysis should be acknowledged. First, the overall outcomes were based on individual unadjusted ORs, whereas a more precise evaluation should be adjusted by potentially suspected factors including age, gender, smoking status, and environmental factors. Second, the controls were not uniformly defined. Although most of the controls were selected mainly from healthy populations, some had benign disease such as liver cirrhosis, HBsAg positive and so on. Therefore, non-differential misclassification bias was possible because these studies may have included the control populations who have different risks of developing HCC. Third, the number of studies included in the meta-analysis for African population was relatively small and there was only one study in the African group, which may lead to low statistical power and generated fluctuate estimation. Finally, gene–environment interactions were not addressed in this meta-analysis due to the lack of sufficient data. As is generally accepted, aside from genetic factors and chronic infection with HBV or HCV, exposure to aflatoxin B1, liver cirrhosis, and habitual alcohol abuse are major risk factors for HCC; however, we could not perform subgroup analyses based on these environmental exposures owing to the limited reported information on such associations in those included studies.

Despite these limitations, this meta-analysis suggests that the MDM2 SNP 309 polymorphism but not TP53 Arg72Pro variant is associated with increased risk of HCC. In addition, our findings further suggest that the combination of MDM2 SNP 309 and TP53 Arg72Pro genotypes confers higher risk to develop HCC. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous HCC patients and well-matched controls. Moreover, gene–environment interactions should also be considered in the analysis. Such studies taking these factors into account may eventually lead to better, comprehensive understanding of the association between these polymorphisms and HCC risk.

**Supporting Information**

**Figure S1** Flow diagram of included studies for this meta-analysis. (TIF)

**Figure S2** Funnel plot analysis to detect publication bias. Each point represents a separate study for the indicated association. A Funnel plot for MDM2 SNP309 polymorphism in the overall analysis (recessive model GG vs. TT+GT; $P = 0.180$); B Funnel plot for TP53 Arg72Pro polymorphism in the overall analysis (recessive model ProPro vs. ArgPro+ArgArg; $P = 0.114$). (TIF)

**Checklist S1** Checklist of items to include when reporting a systematic review or meta-analysis. (DOC)

**Author Contributions**

Conceived and designed the experiments: SL, QP, XL, XQ. Performed the experiments: CM, HL, YD. Analyzed the data: ZC, J. Wang, JS, J. Wu. Contributed reagents/materials/analysis tools: LZ, SY. Wrote the paper: SL, QP, XL, XQ.

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
2. Li Q, Du J, Gnan P, Qiu CF, Dai M (2012). [Estimation and prediction of incidence, mortality and prevalence on liver cancer, in 2008, China]. Zhonghua Bing Bing Xue Za Zhi 33: 534–537.
3. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27–54.
4. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2566.
5. Dragani TA (2010) Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 52: 252–257.
6. Tong WM, Hands MP, Lansdorp PM, Wang QZ (2001) DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosone stability, and tumor suppression. Mol Cell Biol 21: 4046–4054.
7. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53:p21 pathway. Nature 460: 1132–1135.
8. Marte B (2002) Cancer: super p53. Nature 420: 279.
9. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, et al. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function, chromosome stability, and tumor suppression. Mol Cell Biol 21: 4046–4054.
10. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: a comprehensive drug target. Curr Cancer Drug Targets 5: 3–8.
11. Liu Xing Bing Xue Za Zhi 33: 554–557.
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
13. Ma HB, Huang T, Han F, Chen WY (2012) Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev 13: 2891–2896.
14. Tomoda T, Nouse K, Sakai A, Ouchida M, Kobayashi S, et al. (2012) Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol 27: 797–804.
15. Yang Y, Xia T, Li N, Zhang J, Cong W, et al. (2013) Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell 4: 71–81.
16. Jiang D (2008) P53 gene mutation, P53 R72P and MDM2 SNP309 polymorphisms and hepatocellular carcinoma development and prognosis. 4: 1–129.
17. Lv L, Wang F, Zhou X, Sun B (2013) Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol 34: 1429–1434.
18. Ding C, Yu H, Qiu H (2012) TP53 codon 72 polymorphism with hepatocellular carcinoma: a meta-analysis. J Int Med Res 40: 446–454.
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
20. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
21. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2566.
TP53 and MDM2 Gene Polymorphisms and HCC

24. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
26. Zhu ZZ, Gong WM, Liu SF, Xian ZH, Wu WQ, et al. (2005) A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 229: 77–83.
27. Zhu ZZ, Cong WM, Zuo GS, Liu SF, Xian ZH, et al. (2005) [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 632–635.
28. Ezikouri S, El Friedy AE, Chaflal A, Benazzouz M, El Kihal L, et al. (2007) The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 37: 748–754.
29. Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E (2010) MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol Biomarkers Prev 19: 229–233.
30. Di Vulo V, Buonaguro L, Izzo F, Losito S, Botti G, et al. (2011) TP53 and MDM2 polymorphisms in the risk of hepatocellular carcinoma. World J Gastroenterol 15: 5592–5597.
31. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, et al. (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in Chinese population. Jpn J Cancer Res 97: 1196.
32. Ezzikouri S, Esaid El Friedy A, Afifi R, Benazzouz M, Hassar M, et al. (2011) Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers 26: 229–233.
33. Di Vaolo V, Buonaguro L, Izzo F, Losito S, Botti G, et al. (2011) TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer 6: 13.
34. Wang X, Zhang X, Qiu B, Tang Y, Sun H, et al. (2012) MDM2 SNP309T allele is associated with hepatocellular carcinoma in a northeast Han Chinese population. Liver Int 32: 1172–1178.
35. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, et al. (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29: 1192–1196.
36. Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, et al. (2012) p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep 39: 1639–1647.
37. Leven M, Gritt C, Rossi L, Zavaglia C, Givardi E, et al. (2004) Codon 72 polymorphism of p53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 208: 75–79.
38. Yu MW, Yang SY, Chiu YH, Chiang YC, Liao YF, et al. (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29: 697–702.
39. Anzola M, Cuervas N, Lopez-Martinez M, Saiz A, Burgos JJ, et al. (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193: 199–205.
40. Xu Y, Liu L, Liu J, Zhang Y, Zuo J, et al. (2011) A potentially functional polymorphism in the promoter region of mIR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412–417.
41. Son MS, Jiang MJ, Jeon YJ, Kim WH, Kwon CI, et al. (2013) Promoter polymorphisms of p16INK4a and p53 in hepatocellular carcinoma. Gene 524: 156–160.
42. Zhang Y, Fan X, Yu H (2012) Association of p53 Codon72 Polymorphism and Risk of Hepatocellular Carcinoma. J Transl Med 10: 168.
43. Peng T, Yan L, Liu Z, Shen H, Choon N, et al. (2004) Guangxi hepatocellular carcinoma is associated with p53 codon 72 polymorphism. Jpn J Cancer Res 95: 313–315.
44. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714–723.
45. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, et al. (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26767–26777.
46. Barak Y, Joven T, Hafihor R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461–468.
47. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481–5484.
48. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Mol Cell Biol 24: 5191–5199.
49. Hong Y, Miao X, Zhang X, Ding F, Lao A, et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65: 9582–9587.
50. Chan HL, Sung JJ (2006) Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26: 153–161.
51. Castello G, Costantini S, Scala S (2010) Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 8: 109.
52. Chen J, Wu X, Lin J, Levine AJ (1996) mdm2-2 inhibits the G1 arrest and apoptotic functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445–2452.
53. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, et al. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27: 110–117.
54. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
55. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of TP53 and MDM2 gene polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Cancer Lett 208: 75–79.
56. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
57. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
58. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
59. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
60. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.
61. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 67: 9582–9587.